UPJOINT

A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis

Brief summary

Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by the body's immune system mistakenly attacking healthy joint tissue causing inflammation, joint damage, disability, and a reduced life expectancy. The main objective of this study is to characterize attainment of minimal disease activity (MDA) at week 24 under continuous treatment with upadacitinib in participants with oligo- or polyarticular PsA as part of real-world practice. Upadacitinib is a drug approved for the treatment of Psoriatic arthritis (PsA) in Germany and Canada. Approximately 380 adult participants with PsA at multiple sites in Germany and Canada. Participants will receive oral Upadacitinib tablets per current local label, according to local standard of care and international guidelines. There may be a higher burden for participants in this study compared to standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and by questionnaire.

Observational study

Status:
Recruiting
Conditions:
Psoriatic Arthritis
Enrollment:
380 patients
Protocol ID:
P20-483
Observational model:
Cohort
Time perspective:
Prospective

 

Eligibility criteria

Participant attributes:
Male and Female

Age:

18 Years and older.

Inclusion Criteria:

- Diagnosis of active Psoriatic Arthritis (PsA) upon judgment of the treating physician.

- Swollen joint count (SJC) >= 1 out of 66 joints.

- Decision on the treatment with Upadacitinib was made prior to any decision to approach
the participant to participate in this study.

Exclusion Criteria:

- Cannot be treated with Upadacitinib according to the local Upadacitinib Summary of
Product Characteristics (SmPC).

- Prior treatment with Upadacitinib.

- Currently participating in interventional research or within the last 30 days.

All the cities where the clinical studies are located

Vancouver - V5Z 1J9
Barrie - L4M 6L2
Dundas - L9H 1B7
Hamilton - L8N 1Y2
Mississauga - L5M 2V8
Oshawa - L1H 1B9
Ottawa - K1H 7X3
St. Catharines - L2N 7E4
Windsor - N8X 1T3
Montreal - H4N 1C6
Montréal - H4A 3T2
Rimouski - G5L 5T1
Sainte-foy - G1V 3M7
Sherbrooke - J1G 2E8
Trois-rivières - G8Z 1Y2
Saskatoon - S7K 3H3
Winnipeg - R3A 1M3

More information about this study

clinicaltrials.gov